An Open Label, Non-randomized, First-in-human, Multi-centre Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Locally Administered DT01 in Combination With Radiotherapy and Concomitant Dose of Chloroquine in Patients With Metastatic Melanoma With Relapsed Cutaneous Tumors Including Melanoma-in-transit

Trial Profile

An Open Label, Non-randomized, First-in-human, Multi-centre Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Locally Administered DT01 in Combination With Radiotherapy and Concomitant Dose of Chloroquine in Patients With Metastatic Melanoma With Relapsed Cutaneous Tumors Including Melanoma-in-transit

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Jun 2016

At a glance

  • Drugs AsiDNA (Primary) ; AsiDNA (Primary) ; Chloroquine
  • Indications Malignant melanoma
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms DRIIM
  • Sponsors DNA Therapeutics
  • Most Recent Events

    • 16 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 03 May 2016 Results from Phase I part of this study published in the British Journal of Cancer
    • 04 Aug 2015 Results presented at the "Sarcoma and Cutaneous tumors" scientific session on 19th Oct 2015, as per DNA Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top